- TUMOR MICROENVIRONMENT AND METASTASIS PROGRAM Research in the Tumor Microenvironment and Metastasis (TMM) program is directed to defining the mechanisms by which the microenvironment initiates and sustains systemic dissemination of cancers based on interactions between tumor and stromal cells. Program goals include (i) identification of stromal cell types responsible for migratory and disseminating tumor cell phenotypes, (ii) development of in vitro models and cell lines to elucidate the mechanisms for stromal cell induction of tumor cell dissemination, and the discovery of prognostic markers based on these mechanisms, (iii) characterization of molecular mechanisms of growth factor and cytokine actions that regulate cell migration, dissemination, angiogenesis and invasion of distant sites by tumor cells through elucidating intrinsic regulatory, downstream mechanisms, (iv) elucidation of the role of surface molecules and their associated cytoskeletal proteins in tumor cell behavior and metastatic phenotype. A variety of systems are utilized, including cell lines in vitro, animal models in vivo and xenografts, transgenic mouse models of breast cancer and unique biophysical and cell biology tools. A unique aspect of this program is the development of innovative imaging technologies for the study of tumor microenvironment- driven metastasis in vivo that allows documentation of the longitudinal progression of cancers in all sites and stages. These studies encompass: (i) development of large-volume, high-resolution multiphoton intravital imaging to directly observe the initiation of tumors and their dissemination in order to elucidate the underlying mechanisms, (ii) the development of permanent imaging windows for primary and secondary sites for documentation of single cell phenotype, fate and contribution to metastasis, and (iii) the development of novel tumor indwelling microfluidic devices that deliver precise signals to the tumor microenvironment. The over- arching goal of this program, and a major focus since 2013, is the translation of basic mechanistic findings in the laboratory to mouse models with translation to correlative, preventive and therapeutic initiatives in the clinic. Ongoing clinical studies are focused on developing independent, novel correlates of risk of breast cancer progression and metastasis, along with pharmacological interventions in patients conducted by members of the Experimental Therapeutics program. Likewise, there are ongoing studies to translate MRI-based imaging technology from mouse models into imaging protocols in patients that will allow noninvasive in vivo assessment of metastatic risk and response to treatment. While a major focus of research has been on breast cancer, the TMM program now includes research in head and neck, thyroid, pancreatic and other cancers. There are 20 program members from 9 departments. Current NCI funding is 2.3M (dc); total peer-reviewed funding is 4.7M (dc). There have been 297 publications since July 2013 of which 23% represent intra- programmatic, 26% inter-programmatic, and 58% represent collaborations with investigators at other institutions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA013330-48
Application #
9998885
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-06-01
Project End
2022-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
48
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Albert Einstein College of Medicine
Department
Type
DUNS #
081266487
City
Bronx
State
NY
Country
United States
Zip Code
10461
Dulyaninova, Natalya G; Ruiz, Penelope D; Gamble, Matthew J et al. (2018) S100A4 regulates macrophage invasion by distinct myosin-dependent and myosin-independent mechanisms. Mol Biol Cell 29:632-642
Chen, Zigui; Schiffman, Mark; Herrero, Rolando et al. (2018) Classification and evolution of human papillomavirus genome variants: Alpha-5 (HPV26, 51, 69, 82), Alpha-6 (HPV30, 53, 56, 66), Alpha-11 (HPV34, 73), Alpha-13 (HPV54) and Alpha-3 (HPV61). Virology 516:86-101
Heo, Moonseong; Kim, Namhee; Rinke, Michael L et al. (2018) Sample size determinations for stepped-wedge clinical trials from a three-level data hierarchy perspective. Stat Methods Med Res 27:480-489
Kunnath-Velayudhan, Shajo; Porcelli, Steven A (2018) Isolation of intact RNA from murine CD4+ T cells after intracellular cytokine staining and fluorescence-activated cell sorting. J Immunol Methods 456:77-80
Zamurrad, Sumaira; Hatch, Hayden A M; Drelon, Coralie et al. (2018) A Drosophila Model of Intellectual Disability Caused by Mutations in the Histone Demethylase KDM5. Cell Rep 22:2359-2369
Sparano, Joseph A (2018) Prognostic gene expression assays in breast cancer: are two better than one? NPJ Breast Cancer 4:11
Centini, Ryan; Tsang, Mark; Iwata, Terri et al. (2018) Loss of Fnip1 alters kidney developmental transcriptional program and synergizes with TSC1 loss to promote mTORC1 activation and renal cyst formation. PLoS One 13:e0197973
Nadaradjane, Celine; Yang, Chia-Ping Huang; Rodriguez-Gabin, Alicia et al. (2018) Improved Dose-Response Relationship of (+)-Discodermolide-Taxol Hybrid Congeners. J Nat Prod 81:607-615
Tiwari, Sangeeta; van Tonder, Andries J; Vilchèze, Catherine et al. (2018) Arginine-deprivation-induced oxidative damage sterilizes Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 115:9779-9784
Celestrin, Kevin; Díaz-Balzac, Carlos A; Tang, Leo T H et al. (2018) Four specific immunoglobulin domains in UNC-52/Perlecan function with NID-1/Nidogen during dendrite morphogenesis in Caenorhabditis elegans. Development 145:

Showing the most recent 10 out of 1508 publications